Biotech
-
FDA takes major step to ease access to CAR-T therapy
The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ post-treatment movement.
Read More » -
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at…
Read More » -
Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery
Can rethinking risk in R&D unlock breakthroughs for rare and hard-to-treat diseases?
Read More » -
Prothena to lay off majority of staff; Zealand shares obesity drug data
Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a dual-acting…
Read More » -
FDA approves twice-yearly shot of Gilead drug for HIV prevention
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market…
Read More » -
Lilly to acquire Verve in $1B bet on gene editing for heart disease
The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows…
Read More » -
Novo, searching for a spark, plans late-stage trials for amylin drug
The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an…
Read More » -
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company…
Read More » -
SpliceBio lands $135M for a new kind of eye gene therapy
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to…
Read More » -
Merck antibody drug for RSV approved by FDA
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly became a…
Read More »